SCHEMBL1900678

SCHEMBL1900678

CCc1[nH]n[c]c1-c1ccccc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 2/20 0.37
KDM4E B2RXH2 3/20 0.36
ALDH1A1 P00352 3/20 0.36
HSD17B10 Q99714 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.33
RAB9A P51151 2/20 0.32
L3MBTL1 Q9Y468 2/20 0.32
NPC1 O15118 1/20 0.32
POLB P06746 1/20 0.32
NR1H2 P55055 2/20 0.32
NR1H3 Q13133 2/20 0.32
PTGS1 P23219 1/20 0.32
PTGS2 P35354 1/20 0.32
AKT2 P31751 2/20 0.32
CHEK1 O14757 1/20 0.32
AKT1 P31749 1/20 0.32
LMNA P02545 1/20 0.31
DHFR P00374 1/20 0.31
HEXA P06865 1/20 0.31
HEXB P07686 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL624396 0.75 AKT2 (0.42) KDM4EALDH1A1SMN1; SMN2RAB9AL3MBTL1
SCHEMBL4723416 0.74 TTK (0.39) TP53KDM4EALDH1A1HSD17B10SMN1; SMN2
SCHEMBL1386378 0.72 KDM4E (0.41) KDM4EALDH1A1HSD17B10SMN1; SMN2RAB9A
SCHEMBL4724605 0.71 MAPT (0.34) TP53KDM4EALDH1A1HSD17B10SMN1; SMN2
SCHEMBL5449727 0.71 CYP1A2 (0.34) TP53KDM4EALDH1A1SMN1; SMN2RAB9A
SCHEMBL5441989 0.71 MAP2K4 (0.33) KDM4EALDH1A1RAB9AL3MBTL1NPC1
SCHEMBL1902682 0.70 HPGD (0.34) KDM4EALDH1A1L3MBTL1AKT2CHEK1
SCHEMBL1898427 0.70 KDM4E (0.35) TP53KDM4EALDH1A1L3MBTL1AKT2
SCHEMBL558507 0.70 ALDH1A1 (0.37) KDM4EALDH1A1RAB9AL3MBTL1NPC1
SCHEMBL4720944 0.70 CYP2D6 (0.40) CHEK1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8455477-B2 Therapeutic compounds MERCK SHARP & DOHME CORP. (US) 2013-06-04 US disclosed
US-20110207711-A1 Therapeutic Compounds MSD K.K. (JP) 2011-08-25 US disclosed
EP-2320907-A1 THERAPEUTIC COMPOUNDS Merck & Co., Inc. (US) 2011-05-18 EP disclosed
WO-2010017047-A1 THERAPEUTIC COMPOUNDS MERCK & CO., INC. (US) 2010-02-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110207711-A1 Therapeutic Compounds WEE2, MARK3, WEE1 TP53 415/4885KDM4E 1778/4885ALDH1A1 4287/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.